Skip to main content
. 2012 Mar;28(3):282–288. doi: 10.1089/aid.2011.0057

Table 1.

Characteristics of Vertically HIV-Infected Children at Enrollment and at the First Opportunistic Infection After Enrollment on NISDI

Study variable At enrollment N=731 (%) Experiencing an OI on study N=383 (%)
Country of birth
 Brazil 483 (66.1) 285 (74.4)
 Mexico 118 (16.1) 45 (11.8)
 Argentina 71 (9.7) 22 (5.7)
 Peru 37 (5.1) 20 (5.2)
 Jamaica 22 (3.0) 11 (2.9)
Gender
 Male 325 (44.5) 174 (45.4)
 Female 406 (55.5) 209 (54.6)
Age (years)
 Median (QR) 5.0 (3.0–9.0) 6.0 (4.0–10.0)
 <1 37 (5.1) 11 (2.9)
 1-4 275 (37.6) 113 (29.5)
 5-9 280 (38.3) 160 (41.8)
 ≥10 139 (19.0) 99 (25.8)
HIV classification (CDC)
 N 101 (14.0) 39 (10.3)
 A 155 (12.5) 76 (20.1)
 B 233 (32.3) 128 (33.9)
 C 233 (32.3) 135 (35.7)
 Missinga 9 5
ARV regimen
 PI + NNRTI HAART 55 (7.5) 14 (3.6)
 PI HAART 328 (44.9) 186 (48.6)
 NNRTI HAART 103 (14.1) 63 (16.4)
 Other ARV 127 (17.4) 75 (19.6)
 No ARV 118 (16.1) 45 (11.8)
CD4 percent
 Median (QR) 27% (21–34) 26% (19–34)
 <15% 74 (11.5) 49 (14.1)
 15–24% 187 (29.0) 102 (29.4)
 ≥25% 384 (59.5) 196 (56.5)
 Missinga 86 36
HIV viral load (copies/ml)
 Median (QR) 7.9K (0.2–44.3K) 10.5K (0.7–63K)
 <1000 225 (31.0) 100 (26.5)
 1000–<10,000 156 (21.5) 84 (22.2)
 ≥10,000 345 (47.5) 194 (51.3)
 Missinga 5 5
Weight/age (CDC z-score)
 ≤2SD from the mean 118 (16.2) 60 (15.8)
 ±2 SD from the mean 601 (82.4) 318 (83.7)
 >2SD above the mean 10 (1.4) 2 (0.5)
 Missinga 2 3
Height/age (CDC z-score)
 ≤2 SD from the mean 148 (20.4) 74 (19.5)
 ±2 SD from the mean 574 (79.2) 304 (80.2)
 >2 SD above the mean 3 (0.4) 1 (0.3)
 Missinga 6 4
BMI percentile
 <5th percentile 68 (9.4) 42 (11.2)
 5th<95th percentile 615 (84.8) 321 (85.4)
 ≥95th percentile 42 (5.8) 13 (3.4)
 Missinga 6 7
a

Missing values are not included in percentages.

QR, quartile range represents the 25th and 75th quartile for the population; SD, standard deviation; OI, opportunistic infection; ARV, antiretroviral; PI, protease inhibitor; HAART, highly active antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; BMI, body mass index.